Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Virology. 2011 Jan 20;411(2):288–305. doi: 10.1016/j.virol.2010.12.014

Table 3.

Compounds used to treat enterovirus infections

Compound Target Stage of Development BBB Penetration Resistance Mechanism
Ribavirin (Li, 2008) Viral Genome Patient Prescription Conflicting Reports (Hosoya 2001 + Honda 1994) Yes (Poliovirus Isolates) (Vignuzzi, 2005 + Pfeiffer 2003) Nucleoside Analog - Genomic Incorporation- Error Catastrophe
Pleconaril (Pevear, 1999) VP1 Protein of Nucleocapsid Clinical-Phase III-IV (Webster 2005, Desmond 2006) Yes (Schmidtke 2009) Yes (CVB3 Nancy Strain) (Schmidtke 2005) Conformational Change of VP1 Protein - Receptor Attachment - Genomic Uncoating (Chen 2008)
RNAi (Multiple Formulations) Viral Genome – Majority Target Protease 2A + 3C or Polymerase 3D (Yuan, 2005) (Tan 2010) (Tan 2007) In Vitro/In Vivo (Li, 2008) Undocumented Yes (Coxsackie + Poliovirus Isolates) (Merl 2007) (Gitlin 2002) Viral RNA Degradation via Dicer Recognition (Aliyari 2009)